Author:
Dodig Slavica,Čepelak Ivana
Abstract
Graphical abstract
Highlights
• Antiphospholipid syndrome is a rare systemic autoimmune disease characterized by recurrent pregnancy morbidity or thrombosis in combination with the persistent presence of antiphospholipid antibodies in plasma/serum
• Specialists in laboratory medicine should take responsibility for the entire analytical process, so that possible interferences are minimized, and physicians obtain reliable results of the patient’s laboratory findings in a timely manner
• Due to possible problems in performing tests on aPLs for a more reliable (optimal) interpretation of laboratory findings, a close cooperation between laboratory specialists and clinical specialists is needed
Antiphospholipid syndrome (APS) is a rare systemic autoimmune disease characterized by recurrent pregnancy morbidity or thrombosis in combination with the persistent presence of antiphospholipid antibodies (aPLs) in plasma/serum. Antiphospholipid antibodies are a heterogeneous, overlapping group of autoantibodies, of which anti-β2-glycoprotein I (aβ2GPI), anticardiolipin (aCL) antibodies and antibodies that prolong plasma clotting time in tests in vitro known as lupus anticoagulant (LAC) are included in the laboratory criteria for the diagnosis of APS. The presence of LAC antibodies in plasma is indirectly determined by measuring the length of coagulation in two tests - activated partial thromboplastin time (aPTT) and diluted Russell’s viper venom time (dRVVT). The concentration of aβ2GPI and aCL (immunglobulin G (IgG) and immunoglobulin M (IgM) isotypes) in serum is directly determined by solid-phase immunoassays, either by enzyme-linked immunosorbent assay (ELISA), fluoroimmunoassay (FIA), immunochemiluminescence (CLIA) or multiplex flow immunoassay (MFIA). For patient safety, it is extremely important to control all three phases of laboratory testing, i.e. preanalytical, analytical and postanalytical phase. Specialists in laboratory medicine must be aware of interferences in all three phases of laboratory testing, in order to minimize these interferences. The aim of this review was to show the current pathophysiological aspects of APS, the importance of determining aPLs-a in plasma/serum, with an emphasis on possible interferences that should be taken into account when interpreting laboratory findings.
Publisher
Croatian Society for Medical Biochemistry and Laboratory Medicine
Reference66 articles.
1. The 2023 ACR/EULAR Antiphospholipid syndrome classification criteria.;Barbhaiya;Arthritis Rheumatol,2023
2. Guidelines on the investigation and management of antiphospholipid syndrome.;Keeling;Br J Haematol,2012
3. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management.;Knight;BMJ,2023
4. Epidemiology of antiphospholipid syndrome in the general population.;Dabit;Curr Rheumatol Rep,2022
5. The pathophysiology of the antiphospholipid syndrome: A perspective from the blood coagulation system.;Arreola-Diaz;Clin Appl Thromb Hemost,2022